140 filings
Page 3 of 7
6-K
k4bshd8
30 Mar 23
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study
7:15am
6-K
cqdqemy46y1u7i
15 Mar 23
Medicenna Announces Upcoming Presentation at the AACR Annual Meeting
7:30am
6-K
rq40smt
2 Mar 23
Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference
9:17am
6-K
spmqh0b1wpt
17 Feb 23
Current report (foreign)
5:30pm
6-K
l1edtri
7 Feb 23
Interim condensed consolidated financial statements of
8:01am
6-K
k8tu96 jf
31 Jan 23
Medicenna to Present at the 2023 Guggenheim Oncology Conference
8:50am
6-K
c1a630jd75917
26 Jan 23
Current report (foreign)
7:15am
6-K
649xe2l2
5 Jan 23
Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent
9:45am
6-K
bz9 69n8d
10 Nov 22
Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting
9:05am
6-K
cpzfu1mtqiv 8l
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
ubmtxh9j674o4
28 Oct 22
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
8:00am
6-K
qkd67 fyteinxzp
25 Oct 22
Current report (foreign)
7:51am
6-K
z6t4c4oc9wb8bbyzt
17 Oct 22
Current report (foreign)
4:21pm
6-K
uulj luszqmsli
5 Oct 22
Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
8:28am
6-K
wr19t50
30 Sep 22
Current report (foreign)
8:22am
6-K
2doruut
28 Sep 22
Current report (foreign)
9:45am
6-K
85k kcp0tfv
22 Sep 22
Current report (foreign)
4:42pm
6-K
iaiddop acpzo
22 Sep 22
Report of Voting Results
4:41pm
6-K
9exndoy
21 Sep 22
Medicenna Announces Results of Annual Meeting of Shareholders
5:10pm
6-K
e7ciz
13 Sep 22
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial
4:38pm